Table 1.

Demographic and clinical characteristics

	All patients n = 32 (%)	Thrombosis n = 9 (%)	Non-thrombotic n = 23 (%)	P value
Sex (female/male)	21/11	4/5	17/6	0.11
Age (years)	11.7 (1–15)	12.2 (1–15)	11.5 (6–15)	0.93
Evolution time (weeks)	16 (1–108)	7.5 (1–28)	19 (1–108)	0.21
Hematologic	29 (90%)	7 (78%)	22 (96%)
Thrombocytopenia	22 (67%)	7 (78%)	15 (65%)	0.49
AIHA	13 (41%)	2 (22%)	11 (48%)	0.18
LAHP	2 (6%)	0	2 (9%)	0.36
Dermatologic	23 (72%)	7 (78%)	16 (70%)
Livedo reticularis	20 (63%)	7 (78%)	13 (57%)	0.26
Raynaud's phenomenon	8 (25%)	2 (22%)	6 (26%)	0.82
Skin ulcers	2 (6%)	0	2 (9%)	0.36
Neurologic	5 (16%)	1 (11%)	4 (17%)
Migraine	3 (9%)	1 (11%)	2 (9%)	0.83
Cognitive impairment	3 (9%)	1 (11%)	2 (9%)	0.83
Epilepsy	1 (3%)	1 (11%)	0	0.10
Chorea	1 (3%)	0	1 (4%)	0.52
Renal	4 (13%)	3 (33%)	1 (4%)
Nephrotic síndrome	1 (3%)	1 (11%)	0	0.10
Nephritic syndrome	3 (9%)	2 (22%)	1 (4%)	0.11
Clinical profile
T	1 (3%)	1 (11%)	0
H	6 (19%)	0	6 (26%)
R	1 (3%)	1 (11%)	0
C	1 (3%)	0	1 (4%)
H + C	16 (50%)	5 (55%)	11 (48%)
H + N	1 (3%)	0	1 (4%)
H + C + R	2 (6%)	1 (11%)	1 (4%)
H + C + N	3 (9%)	0	3 (13%)
H + C + N + R	1 (3%)	1 (11%)	0

LAHP Lupus anticoagulant with hypoprothrombinemia syndrome, AIHA Autoimmune hemolytic anemia, T Thrombosis, H Hematologic, R Renal, C Cutaneous, N Neurologic